Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production

Venetoclax, a Bcl-2 inhibitor, in combination with the hypomethylating agent azacytidine, achieves complete remission with or without count recovery in ∼70% of treatment-naive elderly patients unfit for conventional intensive chemotherapy. However, the mechanism of action of this drug combination is...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Lee, Jong Bok, Khan, Dilshad H., Hurren, Rose, Xu, Mingjing, Na, Yoosu, Kang, Hyeonjeong, Mirali, Sara, Wang, Xiaoming, Gronda, Marcela, Jitkova, Yulia, MacLean, Neil, Arruda, Andrea, Alaniz, Zoe, Konopleva, Marina Y., Andreeff, Michael, Minden, Mark D., Zhang, Li, Schimmer, Aaron D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Immunobiology and Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8310428/
https://ncbi.nlm.nih.gov/pubmed/34292323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020009081
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados